Total Payments
$504,347
2023 Payments
$21.90
Companies
7
Transactions
41
Payment Breakdown by Category
Other$467,000 (92.6%)
Research$25,651 (5.1%)
Consulting$10,345 (2.1%)
Travel$885.75 (0.2%)
Food & Beverage$465.52 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $467,000 | 2 | 92.6% |
| Unspecified | $25,651 | 22 | 5.1% |
| Consulting Fee | $10,345 | 3 | 2.1% |
| Travel and Lodging | $885.75 | 5 | 0.2% |
| Food and Beverage | $465.52 | 9 | 0.1% |
Payments by Type
General
$478,696
19 transactions
Research
$25,651
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $467,018 | 3 | $0 (2018) |
| Astellas Pharma Global Development | $25,651 | 22 | $0 (2022) |
| Daiichi Sankyo Inc. | $7,466 | 10 | $0 (2018) |
| Janssen Global Services, LLC | $3,146 | 3 | $0 (2018) |
| Agios Pharmaceuticals, Inc. | $1,000 | 1 | $0 (2018) |
| AbbVie, Inc. | $44.71 | 1 | $0 (2018) |
| ConvaTec Inc. | $21.90 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $21.90 | 1 | ConvaTec Inc. ($21.90) |
| 2022 | $1,836 | 2 | Astellas Pharma Global Development ($1,836) |
| 2021 | $9,500 | 11 | Astellas Pharma Global Development ($9,500) |
| 2020 | $8,104 | 4 | Astellas Pharma Global Development ($8,104) |
| 2019 | $6,210 | 5 | Astellas Pharma Global Development ($6,210) |
| 2018 | $244,657 | 16 | Eli Lilly and Company ($233,000) |
| 2017 | $234,018 | 2 | Eli Lilly and Company ($234,018) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/16/2023 | ConvaTec Inc. | AQUACEL AG+ (Device), AQUACEL FOAM | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: ADVANCED WOUND CARE | ||||||
| 09/26/2022 | Astellas Pharma Global Development | Xospata (Drug) | — | In-kind items and services | $94.20 | Research |
| Study: 3294 Physician & Patient Preferences post HSCT • Category: Oncology | ||||||
| 06/14/2022 | Astellas Pharma Global Development | Xospata (Drug) | — | In-kind items and services | $1,742.25 | Research |
| Study: MA-3294 Physician and Patient Preferences for Treatments for Maintece Post-HSCT - manuscript • Category: Oncology | ||||||
| 12/16/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,306.42 | Research |
| Study: Elicitation of patient and physician preferences via discrete-choice experiment (DCE) • Category: ONCOLOGY | ||||||
| 12/16/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $599.91 | Research |
| Study: Maintenance Treatment Landscape and Outcomes in Patients with FLT3mut Acute Myeloid Leukemia who Achieved Complete Remission after First-Line Chemotherapy in Multiple Countries • Category: ONCOLOGY | ||||||
| 11/15/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,026.29 | Research |
| Study: Elicitation of patient and physician preferences via discrete-choice experiment (DCE) • Category: ONCOLOGY | ||||||
| 11/15/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,024.29 | Research |
| Study: Elicitation of patient and physician preferences via discrete-choice experiment (DCE) • Category: ONCOLOGY | ||||||
| 08/23/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,600.00 | Research |
| Study: Maintenance Treatment Landscape and Outcomes in Patients with FLT3mut Acute Myeloid Leukemia who Achieved Complete Remission after First-Line Chemotherapy in Multiple Countries • Category: ONCOLOGY | ||||||
| 08/23/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $649.17 | Research |
| Study: Maintenance Treatment Landscape and Outcomes in Patients with FLT3mut Acute Myeloid Leukemia who Achieved Complete Remission after First-Line Chemotherapy in Multiple Countries • Category: ONCOLOGY | ||||||
| 08/23/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $556.43 | Research |
| Study: Elicitation of patient and physician preferences via discrete-choice experiment (DCE) • Category: ONCOLOGY | ||||||
| 07/26/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,028.43 | Research |
| Study: Elicitation of patient and physician preferences via discrete-choice experiment (DCE) • Category: ONCOLOGY | ||||||
| 07/26/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $556.43 | Research |
| Study: Elicitation of patient and physician preferences via discrete-choice experiment (DCE) • Category: ONCOLOGY | ||||||
| 07/26/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $556.43 | Research |
| Study: Elicitation of patient and physician preferences via discrete-choice experiment (DCE) • Category: ONCOLOGY | ||||||
| 03/11/2021 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $596.43 | Research |
| Study: Physician and Patient Preferences for Treatments of Acute Myeloid Leukemia • Category: ONCOLOGY | ||||||
| 10/19/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $2,539.00 | Research |
| Study: Maintenance Treatment Landscape and Outcomes in Patients with FLT3mut Acute Myeloid Leukemia who Achieved Complete Remission after First-Line Chemotherapy in Multiple Countries • Category: ONCOLOGY | ||||||
| 07/09/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $3,130.00 | Research |
| Study: Maintenance Treatment Landscape and Outcomes in Patients with FLT3mut Acute Myeloid Leukemia who Achieved Complete Remission after First-Line Chemotherapy in Multiple Countries • Category: ONCOLOGY | ||||||
| 05/20/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,600.00 | Research |
| Study: Maintenance Treatment Landscape and Outcomes in Patients with FLT3mut Acute Myeloid Leukemia who Achieved Complete Remission after First-Line Chemotherapy in Multiple Countries • Category: ONCOLOGY | ||||||
| 03/11/2020 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $835.00 | Research |
| Study: Maintenance Treatment Landscape and Outcomes in Patients with FLT3mut Acute Myeloid Leukemia who Achieved Complete Remission after First-Line Chemotherapy in Multiple Countries • Category: ONCOLOGY | ||||||
| 11/12/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,380.00 | Research |
| Study: Economic Burden of Relapse after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia AML in the United States US • Category: ONCOLOGY | ||||||
| 09/18/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,380.00 | Research |
| Study: Economic Burden of Relapse after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia AML in the United States US • Category: ONCOLOGY | ||||||
| 08/28/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,500.00 | Research |
| Study: Treatment Patterns and Key Healthcare Resource utilization in Acute Myeloid Leukemia AML with and without FLT3 Mutation • Category: ONCOLOGY | ||||||
| 08/28/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $1,200.00 | Research |
| Study: Economic Burden of Relapse after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia AML in the United States US • Category: ONCOLOGY | ||||||
| 06/26/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $750.00 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation • Category: ONCOLOGY | ||||||
| 12/24/2018 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $233,000.00 | General |
| 12/20/2018 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Maintenance Treatment Landscape and Outcomes in Patients with FLT3mut Acute Myeloid Leukemia who Achieved Complete Remission after First-Line Chemotherapy in Multiple Countries | Astellas Pharma Global Development | $10,953 | 7 |
| Elicitation of patient and physician preferences via discrete-choice experiment (DCE) | Astellas Pharma Global Development | $6,055 | 7 |
| Economic Burden of Relapse after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia AML in the United States US | Astellas Pharma Global Development | $3,960 | 3 |
| MA-3294 Physician and Patient Preferences for Treatments for Maintece Post-HSCT - manuscript | Astellas Pharma Global Development | $1,742 | 1 |
| Treatment Patterns and Key Healthcare Resource utilization in Acute Myeloid Leukemia AML with and without FLT3 Mutation | Astellas Pharma Global Development | $1,500 | 1 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation | Astellas Pharma Global Development | $750.00 | 1 |
| Physician and Patient Preferences for Treatments of Acute Myeloid Leukemia | Astellas Pharma Global Development | $596.43 | 1 |
| 3294 Physician & Patient Preferences post HSCT | Astellas Pharma Global Development | $94.20 | 1 |
About Dr. James Griffin, MD
Dr. James Griffin, MD is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033175112.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Griffin, MD has received a total of $504,347 in payments from pharmaceutical and medical device companies, with $21.90 received in 2023. These payments were reported across 41 transactions from 7 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($467,000).
Ad
Practice Information
- Specialty Medical Oncology
- Location Boston, MA
- Active Since 04/26/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1033175112
Products in Payments
- XOSPATA (Drug) $23,814
- Xospata (Drug) $1,836
- TIBSOVO (Drug) $1,000
- Venclexta (Drug) $44.71
- AQUACEL AG+ (Device) $21.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Medical Oncology $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Medical Oncology $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Medical Oncology $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Medical Oncology $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701
Medical Oncology $610,701